Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion-Reference-Cited by-同舟云学术

Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion

Published:2020-08-31 Issue:12 Volume:5 Page:1532-1541
ISSN:2058-5276
Container-title:Nature Microbiology
language:en
Short-container-title:Nat Microbiol

Author:

Ma Christopher D.^ORCID,Imamura Michio,Talley Daniel C.,Rolt Adam,Xu Xin,Wang Amy Q.,Le Derek,Uchida Takuro,Osawa Mitsutaka,Teraoka Yuji,Li Kelin,Hu Xin,Park Seung Bum,Chalasani Nishanth,Irvin Parker H.,Dulcey Andres E.,Southall Noel,Marugan Juan J.,Hu Zongyi,Chayama Kazuaki,Frankowski Kevin J.^ORCID,Liang Tsanyang Jake^ORCID

Funder

Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA

Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health, USA

Japan Agency for Medical Research and Development

Kansas University | School of Medicine, University of Kansas

Molecular Libraries Initiative funding to the University of Kansas Specialized Chemistry Center

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Microbiology (medical),Genetics,Applied Microbiology and Biotechnology,Immunology,Microbiology

Link

https://www.nature.com/articles/s41564-020-0781-2.pdf

Reference51 articles.

1. Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161–176 (2017).

2. Jafari, S., Copes, R., Baharlou, S., Etminan, M. & Buxton, J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int. J. Infect. Dis. 14, e928–e940 (2010).

3. Blackard, J. T., Shata, M. T., Shire, N. J. & Sherman, K. E. Acute hepatitis C virus infection: a chronic problem. Hepatology 47, 321–331 (2008).

4. Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907–1917 (2013).

5. Liang, T. J. & Ghany, M. G. Therapy of hepatitis C—back to the future. N. Engl. J. Med 370, 2043–2047 (2014).

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo;Viruses;2023-08-30

2. An entropic safety catch controls hepatitis C virus entry and antibody resistance;eLife;2022-07-07

3. Inhibitors Targeting Hepatitis C Virus (HCV) Entry;Mini-Reviews in Medicinal Chemistry;2022-04-28

4. Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors;mBio;2022-02-22

5. Targeting the Virus Capsid as a Tool to Fight RNA Viruses;Viruses;2022-01-18